Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neutropenia 2Breast Neoplasms 2

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × eflapegrastim × Clear all
NCT02643420 2022-03-02

ADVANCE

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
406 enrolled 19 charts
Breast

Breast Neoplasms, Neutropenia

NCT02953340 2022-03-02

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Spectrum Pharmaceuticals, Inc

Phase 3 Completed
237 enrolled 18 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡